vulvar neoplasms

Summary

Summary: Tumors or cancer of the VULVA.

Top Publications

  1. ncbi Vulvar cancer
    Timothy P Canavan
    Department of Family and Community Medicine, Lancaster General Hospital, Pennsylvania, USA
    Am Fam Physician 66:1269-74. 2002
  2. ncbi Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia
    Gemma G Kenter
    Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands
    N Engl J Med 361:1838-47. 2009
  3. ncbi Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis
    Hugo De Vuyst
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Int J Cancer 124:1626-36. 2009
  4. ncbi HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women
    Maura L Gillison
    Division of Viral Oncology, Johns Hopkins, Kimmel Cancer Center, Baltimore, Maryland 21231, USA
    Cancer 113:3036-46. 2008
  5. ncbi Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer
    U Beller
    Int J Gynaecol Obstet 95:S7-27. 2006
  6. pmc Prognostic significance of c-KIT in vulvar cancer: bringing this molecular marker from bench to bedside
    Beatriz de Melo Maia
    Anatomic Pathology Department, Hospital AC Camargo, Rua Antonio Prudente, 109, 1o Andar Patologia Investigativa, Liberdade, Sao Paulo, SP, CEP 01509 900, Brazil
    J Transl Med 10:150. 2012
  7. ncbi Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors
    M Inoue
    Department of Obstetrics and Gynecology, School of Medicine, Osaka University, Japan
    Cancer Res 54:3049-53. 1994
  8. ncbi HPV related VIN: highly proliferative and diminished responsiveness to extracellular signals
    Lindy A M Santegoets
    Department of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Int J Cancer 121:759-66. 2007
  9. ncbi Local and regional recurrence of vulval cancer: management dilemmas
    John Coulter
    Department of Gynaecology, Coombe Women s Hospital, Dublin, Ireland
    Best Pract Res Clin Obstet Gynaecol 17:663-81. 2003
  10. ncbi Trends in the incidence of invasive and in situ vulvar carcinoma
    Patricia L Judson
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Obstet Gynecol 107:1018-22. 2006

Detail Information

Publications250 found, 100 shown here

  1. ncbi Vulvar cancer
    Timothy P Canavan
    Department of Family and Community Medicine, Lancaster General Hospital, Pennsylvania, USA
    Am Fam Physician 66:1269-74. 2002
    ..Treatment is surgical resection, with the goal being complete removal of the tumor. There has been a recent trend toward more conservative surgery to decrease psychosexual complications...
  2. ncbi Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia
    Gemma G Kenter
    Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands
    N Engl J Med 361:1838-47. 2009
    ..Spontaneous regression occurs in less than 1.5% of patients, and the rate of recurrence after treatment is high...
  3. ncbi Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis
    Hugo De Vuyst
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Int J Cancer 124:1626-36. 2009
    ..This proportion would be similar for the corresponding high-grade lesions of the vagina and anus, but higher for VIN2/3 (75%) than for vulvar carcinoma...
  4. ncbi HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women
    Maura L Gillison
    Division of Viral Oncology, Johns Hopkins, Kimmel Cancer Center, Baltimore, Maryland 21231, USA
    Cancer 113:3036-46. 2008
    ....
  5. ncbi Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer
    U Beller
    Int J Gynaecol Obstet 95:S7-27. 2006
  6. pmc Prognostic significance of c-KIT in vulvar cancer: bringing this molecular marker from bench to bedside
    Beatriz de Melo Maia
    Anatomic Pathology Department, Hospital AC Camargo, Rua Antonio Prudente, 109, 1o Andar Patologia Investigativa, Liberdade, Sao Paulo, SP, CEP 01509 900, Brazil
    J Transl Med 10:150. 2012
    ....
  7. ncbi Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors
    M Inoue
    Department of Obstetrics and Gynecology, School of Medicine, Osaka University, Japan
    Cancer Res 54:3049-53. 1994
    ..The present study suggests that the c-kit/SCF system may play an important role in the carcinogenesis of the female genital tract...
  8. ncbi HPV related VIN: highly proliferative and diminished responsiveness to extracellular signals
    Lindy A M Santegoets
    Department of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Int J Cancer 121:759-66. 2007
    ..Upon reviewing apoptosis and angiogenesis, it was observed that these processes have not become significantly disregulated in VIN...
  9. ncbi Local and regional recurrence of vulval cancer: management dilemmas
    John Coulter
    Department of Gynaecology, Coombe Women s Hospital, Dublin, Ireland
    Best Pract Res Clin Obstet Gynaecol 17:663-81. 2003
    ..Palliative medicine should be integrated early in the management plan both in patients with incurable recurrent disease and in those undergoing potentially curative treatments...
  10. ncbi Trends in the incidence of invasive and in situ vulvar carcinoma
    Patricia L Judson
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Obstet Gynecol 107:1018-22. 2006
    ..To characterize the incidence of vulvar carcinoma in situ and vulvar cancer over time...
  11. ncbi Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer
    C Levenback
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Gynecol Oncol 83:276-81. 2001
    ..To determine the effectiveness of intraoperative lymphatic with blue dye alone as a means of localizing sentinel nodes in patients with vulvar cancer...
  12. pmc The economic burden of noncervical human papillomavirus disease in the United States
    Delphine Hu
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Obstet Gynecol 198:500.e1-7. 2008
    ....
  13. ncbi Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins
    Emma J Davidson
    Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom
    Cancer Res 63:6032-41. 2003
    ..Local immune infiltration may be a critical factor in potential responsiveness to vaccine therapy in HPV-associated neoplasia and should be carefully monitored in future placebo-controlled trials of immunotherapy for VIN...
  14. ncbi TGF-alpha, c-erbB-2 expression and neoangiogenesis in vulvar squamous cell carcinoma
    Peer Hantschmann
    Department of Gynecology and Obstetrics, Kreisklinik Altöting, 84503 Altötting, Germany
    Anticancer Res 25:1731-7. 2005
    ..Thus, we analyzed TGF-alpha c-erbB-2 and tumor neoangiogenesis in vulvar carcinoma and determined their prognostic significance...
  15. ncbi Prognostic significance of CD4+ and CD8+ T cell infiltration within cancer cell nests in vulvar squamous cell carcinoma
    Jacek Jan Sznurkowski
    Department of Gynaecology and Gynaecological Oncology, Medical University of Gdansk, Gdansk, Poland
    Int J Gynecol Cancer 21:717-21. 2011
    ..The purpose of this study was to clarify the role of the subtypes of tumor-infiltrating lymphocytes, both individually and synergistically...
  16. ncbi Epidemiology of vulvar and vaginal cancer in Germany
    C Dittmer
    Department of Obstetrics and Gynaecology, University Medical Center Schleswig Holstein, Lubeck, Germany
    Arch Gynecol Obstet 284:169-74. 2011
    ..At present, epidemiological data are rather scarce. This review article provides an epidemiologic overview of these diseases, focussing on recent German data...
  17. ncbi Characterization of sociodemographic and clinicopathological features in Brazilian patients with vulvar squamous cell carcinoma
    Beatriz de Melo Maia
    Anatomic Pathology Department, Hospital A C Camargo, Sao Paulo, Brazil beatriz melomaia gmail com
    Gynecol Obstet Invest 75:53-60. 2013
    ..Data regarding the epidemiological aspects of this tumor are scarce...
  18. ncbi Surgery and radiotherapy in vulvar cancer
    J A de Hullu
    Department of Gynaecologic Oncology, Radboud University Nijmegen Medical Centre, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Crit Rev Oncol Hematol 60:38-58. 2006
    ....
  19. ncbi Cyclins D1, D3, E, and A in vulvar carcinoma patients
    Synne Knopp
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Montebello, 0310 Oslo, Norway
    Gynecol Oncol 97:733-9. 2005
    ..The aim of this study was to characterize the expression of cyclins D1, D3, E, and A in a comparatively large series of patients with vulvar squamous cell carcinoma and look for prognostic impact...
  20. ncbi Expression of endogenous hypoxia markers in vulvar squamous cell carcinoma
    Yu Zhu Li
    Department of Integrated Traditional Chinese and Western Medicine, Qilu Hospital, Shandong University, China
    Asian Pac J Cancer Prev 13:3675-80. 2012
    ..To investigate the expression of endogenous hypoxia-related markers identified as being involved in vulvar squamous cell carcinoma (VSCC)...
  21. pmc Vulvar squamous cell carcinoma with sarcoma-like stroma: a case report and review of the literature
    Marco Petrillo
    Department of Oncology, Catholic University, Campobasso, Italy
    Diagn Pathol 6:95. 2011
    ..A revision of the currently published cases have been also provided...
  22. ncbi A comparison of quality of life between vulvar cancer patients after sentinel lymph node procedure only and inguinofemoral lymphadenectomy
    M H M Oonk
    Department of Obstetrics and Gynecology, University Medical Center Groningen, Groningen, The Netherlands
    Gynecol Oncol 113:301-5. 2009
    ..Moreover, it was evaluated what patients would advise relatives on the application of the SLN-procedure in light of possible false negative results...
  23. ncbi Prognostication of vulvar cancer based on p14ARF status: molecular assessment of transcript and protein
    André Mourão Lavorato-Rocha
    Department of Anatomic Pathology, Cancer Hospital AC Camargo, Sao Paulo, Brazil
    Ann Surg Oncol 20:31-9. 2013
    ..This study was designed to determine the prognostic role of p14ARF in vulvar squamous cell carcinoma (VSCC)...
  24. ncbi New FIGO staging system of vulvar cancer indeed provides a better reflection of prognosis
    S van der Steen
    Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Gynecol Oncol 119:520-5. 2010
    ..To find out whether the new FIGO staging system (introduced 2009) indeed leads to a more specific prediction of the survival for patients with vulvar SCC...
  25. ncbi Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia
    Emma J Davidson
    Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    J Gen Virol 84:2089-97. 2003
    ..In spite of previous studies showing the immunogenicity of E2 in eliciting primary T-cell responses in vitro, there was a low prevalence of E2 responses in the VIN patients and controls (2/18 vs 0/17)...
  26. ncbi Lesions of anogenital mammary-like glands: an update
    Dmitry V Kazakov
    Sikl s Department of Pathology, Charles University Medical Faculty Hospital, Alej Svobody 80, Pilsen, Czech Republic
    Adv Anat Pathol 18:1-28. 2011
    ..This will enable their recognition, precise classification and should introduce greater uniformity in how they are reported in the literature so that more meaningful clinicopathological comparisons and correlations may be made...
  27. ncbi Sentinel node dissection is safe in the treatment of early-stage vulvar cancer
    Ate G J van der Zee
    Department of Obstetrics and Gynecology, University Medical Center Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands
    J Clin Oncol 26:884-9. 2008
    ..To investigate the safety and clinical utility of the sentinel node procedure in early-stage vulvar cancer patients...
  28. ncbi Role of TP53 mutations in vulvar carcinomas
    Matthias Choschzick
    Institute of Pathology, Department of Gynaecology, University Medical Centre Hamburg Eppendorf, Martinistrasse 52, Hamburg, Germany
    Int J Gynecol Pathol 30:497-504. 2011
    ..These data support the potential utility of restoring TP53 function as a therapeutic alternative in vulvar cancer. Further studies are necessary to clarify the prognostic implications of TP53 mutations in vulvar carcinomas...
  29. ncbi Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses
    Isabelle Bourgault Villada
    Service de Dermatologie and Service d Anatomie pathologique, Université Versailles Saint Quentin en Yvelines, Hopital Ambroise Pare, Boulogne Billancourt, France
    Cancer Res 64:8761-6. 2004
    ..Hence, an increase of HPV-specific effector T lymphocyte responses by vaccine-based therapeutic strategies might be useful to clear the lesions in bowenoid papulosis disease...
  30. ncbi Prognostic factors for recurrence and survival in primary vulvar squamous cell cancer
    Ali Ayhan
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Baskent University Faculty of Medicine, Ankara, Sihhiye, Turkey
    Acta Obstet Gynecol Scand 87:1143-9. 2008
    ..To evaluate survival estimates and clinico-pathological variables in women with primary vulvar squamous cancer...
  31. ncbi Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways
    I A M van der Avoort
    Department of Obstetrics and Gynaecology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Int J Gynecol Pathol 25:22-9. 2006
    ..First, an HPV-dependent pathway with a remarkable resemblance to CIN lesions and cervical carcinoma and second, an HPV-independent pathway in which differentiated VIN III lesions that are hr-HPV-negative may be precursors...
  32. pmc Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
    Zhihui Wang
    Department of Pathology, Oslo University Hospital and University of Oslo, Norway
    BMC Cancer 10:233. 2010
    ..To shed light on their roles in the pathogenesis and to clarify their prognostic values, expression of CDC25A, CDC25B and CDC25C in a large series of vulvar squamous cell carcinomas were examined...
  33. ncbi Carcinoma of the vulva
    Frederick B Stehman
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Obstet Gynecol 107:719-33. 2006
    ..Adequately powered trials aimed at further reducing morbidity without compromising survival are underway...
  34. ncbi Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients
    Manon van Seters
    Department of Gynecology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Gynecol Oncol 97:645-51. 2005
    ..To establish the true natural history of VIN III from literature data...
  35. ncbi The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN)
    Monica Srodon
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Am J Surg Pathol 30:1513-8. 2006
    ..Finally, comparison of the distribution of HPV in the vagina and vulva suggests that VaIN is more closely related to cervical intraepithelial neoplasia than to VIN...
  36. ncbi Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: a prospective trial
    Richard G Moore
    Program in Women s Oncology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 109:65-70. 2008
    ..The objective of this study was to examine the inguinal recurrence rate along with complication rates for patients undergoing inguinal SLN dissection alone for vulvar carcinoma...
  37. ncbi Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva
    Monica Santos
    Departments of Pathology, Hospital Clínic Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, School of Medicine, Barcelona, Spain
    Int J Gynecol Pathol 23:206-14. 2004
    ..In conclusion, p16 immunostaining is a good discriminator between HPV-associated and HPV-unrelated vulvar carcinomas and VIN, although it cannot differentiate basaloid squamous and basal cell carcinoma...
  38. ncbi p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas
    Synne Knopp
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, 0310 Oslo, Norway
    Gynecol Oncol 95:37-45. 2004
    ..Little is known, however, about their clinical impact in vulvar carcinoma patients. Thus, we analyzed a larger series of vulvar squamous cell carcinomas and compared the results with clinical outcome...
  39. pmc Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States
    A M Stroup
    University of Utah, Utah Cancer Registry, 650 Komas Drive, Suite 106B, Salt Lake City, Utah 84108, USA
    Gynecol Oncol 108:577-83. 2008
    ..Describe the treatment and survival patterns among a population-based sample of vulvar cancer patients diagnosed in the United States in 1999...
  40. ncbi Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva
    Francesco Raspagliesi
    Department of Gynecologic Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Gynecol Oncol 102:333-7. 2006
    ..The objective of this study was the prognostic analysis of clinicopathologic variables related to primary tumor and to lymph node metastases...
  41. ncbi Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR
    Magdalena Kowalewska
    Department of Molecular Biology, Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Int J Cancer 116:957-62. 2005
    ..Our findings clearly indicate potential value of CA9 as a molecular marker for the assessment of regional lymph node status in vulvar cancer patients and support a possible utility of our RT-PCR assay in the detection of micrometastases...
  42. ncbi The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva
    Angela Katz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:409-18. 2003
    ..To evaluate treatment of the inguinal nodes for patients with squamous cell carcinoma of the vulva...
  43. ncbi Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one?
    David H Moore
    Gynecologic Oncology of Indiana, Indianapolis, IN 46237, USA
    Gynecol Oncol 113:379-83. 2009
    ..Nonetheless, patients with locally advanced vulva cancer have derived considerable benefit from chemoradiation studies in other related tumor sites, and will continue to do so in the future...
  44. ncbi Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer
    Monika Hampl
    Department of Gynecology and Obstetrics, Institute of Pathology, University Hospital, Heinrich Heine University, Duesseldorf, Germany
    Obstet Gynecol 108:1361-8. 2006
    ..We assessed the prevalence of HPV (and the types) to estimate the possible effect of a HPV vaccine on lower genital tract disease prevention...
  45. ncbi Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age
    Hedwig P van de Nieuwenhof
    Department of Obstetrics and Gynaecology 791, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Eur J Cancer 45:851-6. 2009
    ....
  46. ncbi Recurrent vulvar cancer
    José Alberto Fonseca-Moutinho
    Portuguese Cancer Institute, Surgical Department Gynecology, Coimbra, Portugal
    Clin Obstet Gynecol 48:879-83. 2005
  47. ncbi The role of angiogenesis and COX-2 expression in the evolution of vulvar lichen sclerosus to squamous cell carcinoma of the vulva
    Maria Rosaria Raspollini
    Department of Human Pathology and Oncology, School of Medicine University of Florence, Viale G B Morgagni, 85 50134 Florence, Italy
    Gynecol Oncol 106:567-71. 2007
    ..We aimed to determine whether premalignant changes in vulvar lichen sclerosus (LS) could be identified by analysing markers of angiogenesis and the expression of the enzyme cyclooxygenase-2 (COX-2)...
  48. ncbi Incidence of in situ and invasive vulvar cancer in the US, 1998-2003
    Mona Saraiya
    Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA
    Cancer 113:2865-72. 2008
    ..To provide a baseline picture before HPV vaccine implementation, the authors described vulvar cancer epidemiology by age, race, ethnicity, and histology in the US...
  49. ncbi Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer
    Linn Woelber
    Department of Gynaecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Anticancer Res 29:545-52. 2009
    ..The aim of this study was to determine prognostic variables for recurrence and survival and to identify patterns of recurrence in patients with vulvar cancer...
  50. ncbi Prognostic factors in patients with carcinoma of the vulva--our own experience and literature review
    P Blecharz
    Center of Oncology, Gynecologic Oncology Department, M Sklodowska Curie Memorial Institute, Krakow Branch, Krakow, Poland
    Eur J Gynaecol Oncol 29:260-3. 2008
    ..The objective was the analysis of prognostic factors and treatment outcomes of 104 patients with vulvar cancer, treated between 1990 and 2003 in the Center of Oncology, Maria Sklodowska-Curie Memorial Institute, Cracow, Poland...
  51. ncbi Recurrence patterns and prognostic factors in Chinese patients with squamous cell carcinoma of the vulva treated with primary surgery
    Xi Cheng
    Department of Gynecological Oncology, Cancer Hospital of Fudan University, Shanghai, China
    Int J Gynecol Cancer 19:158-62. 2009
    ..Local recurrence was the main recurrence pattern after primary surgery which would be improved by multidisciplinary treatment...
  52. ncbi Patterns and frequency of recurrences of squamous cell carcinoma of the vulva
    Jorien M Woolderink
    Department of Gynaecological Oncology CMC V, University Medical Center Groningen, University of Groningen, 4th Floor, PO Box 30 001, 9700 RB Groningen, The Netherlands
    Gynecol Oncol 103:293-9. 2006
    ....
  53. ncbi Invasive vulvar cancer in a woman with human immunodeficiency virus: case report and review of the literature
    L Elit
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, McMaster University, Juravinski Cancer Centre, 699 Concession Street, Hamilton, Ontario, Canada
    Gynecol Oncol 98:151-4. 2005
    ..HIV is associated with a decrease in cellular immunity which allows for persistence of high-risk HPV types and this can predispose the woman to dysplasia or cancer of the gynecologic tract...
  54. ncbi A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice
    S Knopp
    Division of Pathology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Montebello, Oslo, Norway
    J Clin Pathol 62:212-8. 2009
    ..Therefore, the investigated markers have not yet earned a place in standard clinical diagnostics or treatment, and further studies are needed to clarify the clinical value of these markers...
  55. ncbi Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors
    Jennifer S Smith
    Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina 27599 7435, USA
    Obstet Gynecol 113:917-24. 2009
    ..Our aim was to conduct a systematic review of HPV type distribution in vulvar and vaginal invasive carcinomas, vulvar intraepithelial neoplasia (VIN), and vaginal intraepithelial neoplasia...
  56. ncbi Stage IA vulvar squamous cell carcinoma: an analysis of tumor invasive characteristics and risk
    Brian J Yoder
    Department of Pathology, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Am J Surg Pathol 32:765-72. 2008
    ..The 3 most important features of stage IA tumors in predicting tumor recurrence were the depth of invasion, presence of SCC at the surgical margins, and the histologic grade...
  57. ncbi Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva
    Jesus Gonzalez Bosquet
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Gynecologic Surgery, Mayo Clinic Rochester, SW Rochester, MN 55905, USA
    Gynecol Oncol 105:742-6. 2007
    ..Assess whether the identified pattern of lymphatic spread supports the current surgical practice of assessing contralateral nodes for lateral lesions with ipsilateral nodal involvement...
  58. ncbi Genetic abnormalities and HPV status in cervical and vulvar squamous cell carcinomas
    Fung Yu Huang
    Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, 6 F, Professorial Block, Pokfulam Road, Hong Kong, China
    Cancer Genet Cytogenet 157:42-8. 2005
    ....
  59. ncbi The accuracy of the sentinel node procedure after excision biopsy in squamous cell carcinoma of the vulva
    Emma J Crosbie
    Department of Gynaecological Oncology, the Christie NHS Foundation Trust, Manchester, UK
    Surg Oncol 19:e150-4. 2010
    ..A prospective study was conducted to determine the diagnostic accuracy of the Sentinel Lymph Node (SLN) procedure in vulval cancer patients referred following either diagnostic or excision biopsy...
  60. ncbi Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases
    D A Santeufemia
    SOC Oncology Santa Maria degli Angeli Hospital Pordenone, Italy
    Eur J Gynaecol Oncol 33:421-2. 2012
    ....
  61. ncbi Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases
    A al-Ghamdi
    Department of Pathology, University of British Columbia and British Columbia Cancer Agency, Vancouver, British Columbia V6T 2B5, Canada
    Gynecol Oncol 84:94-101. 2002
    ..The aim of this study was to examine clinical and pathological features of ISCC presenting in women younger than 40 years of age...
  62. ncbi Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma
    R A De Jong
    Department of Gynecologic Oncology, University of Groningen, Groningen, The Netherlands
    Gynecol Oncol 125:186-93. 2012
    ..Evidence indicating a prognostic role of the immune system in vulvar carcinoma is scarce. This study investigated the presence and prognostic significance of several aspects of the immune system in vulvar squamous carcinoma...
  63. ncbi Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment
    Linn Woelber
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Int J Gynecol Cancer 22:503-8. 2012
    ..However, information regarding the impact of the number of positive nodes in vulvar cancer is inconsistent, and so are recommendations when to apply adjuvant radiotherapy...
  64. ncbi Human papillomavirus-negative spindle cell carcinoma of the vulva associated with lichen sclerosus: case report and literature review
    Angel Santos-Briz
    Departaments of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain
    Am J Dermatopathol 24:135-8. 2002
    ..HPV testing by polymerase chain reaction was negative. In addition, we review the clinicopathologic findings of the four well-documented cases of vulvar SC that have been reported previously in the English language literature...
  65. ncbi Sarcomatoid squamous cell carcinoma of the vulva expressing smooth muscle actin and S100 protein
    Tadashi Terada
    Department of Pathology, Shizuoka City Shimizu Hospital, Miyakami 1231 Shimizu Ku, Shizuoka 424 8636, Japan
    Arch Gynecol Obstet 283:1103-6. 2011
    ..Vulvar sarcomatoid squamous cell carcinoma has been rarely reported...
  66. ncbi Vulvar cancer: prognostic factors
    Maria Ornella Nicoletto
    Medical Oncology Unit, Istituto Oncologico Veneto IRCCS, Via Gattamelata, 64, 35128 Padova, Italy
    Anticancer Res 30:2311-7. 2010
    ..Prognostic factors such as surgery and pathology in vulvar squamous cell carcinoma are studied...
  67. ncbi Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests
    Jacek J Sznurkowski
    Department of Gynaecology and Gynaecological Oncology, The Medical University, Gdansk, Poland
    Gynecol Oncol 122:307-12. 2011
    ..The aim of this study was to evaluate the expression of factor forkhead boxP3 (FOXP3), a marker of Tregs, and IDO in vulvar squamous cell carcinoma (vSCC), and to verify their prognostic significance...
  68. ncbi Histopathological work-up and interpretation of sentinel lymph nodes removed for vulvar squamous cell carcinoma
    Sigrid Regauer
    Institute of Pathology, Working groups of Dermatopathology and Gynaecopathology, Medical University Graz, Auenbruggerplatz 25, Graz A 8036, Austria
    Histopathology 55:174-81. 2009
    ..Patients with missed inguinal disease, however, have a risk of dying from systemic disease. SLN dissections reduce morbidity, but work-up should reliably identify metastatic disease...
  69. ncbi Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977-1991
    M Scheistrøen
    Department of Gynecologic Oncology, Norwegian Radium Hospital, Oslo
    Eur J Gynaecol Oncol 23:93-103. 2002
    ..To evaluate different surgical approaches in early squamous vulvar cancer...
  70. ncbi Cytological evaluation correlates poorly with histological diagnosis of vulvar neoplasias
    Victoria L Bae-Jump
    Division of Gynecologic Oncology, Department of Ob Gyn, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7570, USA
    J Low Genit Tract Dis 11:8-11. 2007
    ..To determine whether cytological smears of the vulva correlate with vulvar biopsies of vulvar intraepithelial neoplasias (VINs)...
  71. ncbi Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value
    Roman Rouzier
    Department of Obstetrics and Gynecology, Centre Hospitalier Intercommunal de Creteil, France
    Obstet Gynecol 100:1159-67. 2002
    ..4% (+/- 18.3%) at 1 year and 70.9% (+/- 17.6%) at 3 years.Local relapses at the site of the primary tumor or skin bridge recurrences are strong predictors for cancer-related death, but not local relapse at a distant site...
  72. ncbi The impact of improving outcomes guidance on surgical management of vulval squamous cell cancer in southwest England (1997-2002)
    A D Falconer
    Department of Gynaecology, Derriford Hospital, Plymouth, UK
    BJOG 114:391-7. 2007
    ....
  73. ncbi Terminology for vulvar cytology based on the Bethesda System
    Matías Jiménez-Ayala
    Department of Pathology, Hospital Universitario Gregorio Maranon, Hospital Universitario de Getafe, Madrid, Spain
    Acta Cytol 46:645-50. 2002
    ..To present a new terminology for vulvar cytology based on the Bethesda System...
  74. ncbi Vulvar cancer in young women: demographic features and outcome evaluation
    Grainger S Lanneau
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Am J Obstet Gynecol 200:645.e1-5. 2009
    ..The objective of the study was to identify prognostic and environmental factors associated with vulvar carcinoma in young women...
  75. ncbi The frequency of human papillomavirus infection in polish patients with vulvar squamous cell carcinoma
    Magdalena Kowalewska
    Department of Molecular Biology, The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, 5 W K Roentgena, 02 781 Warsaw, Poland
    Int J Gynecol Cancer 20:434-7. 2010
    ..In contrast to the established relationship of virtually all cervical cancer cases with the human papillomavirus (HPV) infection, the reported HPV positivity in vulvar carcinoma ranges widely...
  76. ncbi Vulvar cancer patients' quality of life: a qualitative assessment
    M Janda
    Centre for Public Health Research, Queensland University of Technology, Kelvin Grove, QLD, Australia
    Int J Gynecol Cancer 14:875-81. 2004
    ..Results of this study revealed vulvar cancer-specific reductions in QOL for inclusion in the newly developed vulvar cancer-specific subscale...
  77. ncbi The use of cytospin monolayer technique in the cytological diagnosis of vulval and anal disease
    T S Levine
    Department of Histopathology and Cytopathology, The Royal Free Hospital NHS Trust, London, UK
    Cytopathology 12:297-305. 2001
    ..The cytospin monolayer technique allows the diagnosis of neoplastic from non-neoplastic vulval disease. It is a quick, inexpensive and non-invasive method that may have a role in diagnosis, screening and surveillance of patients...
  78. ncbi Specific intraepithelial localization of mast cells in differentiated vulvar intraepithelial neoplasia and its possible contribution to vulvar squamous cell carcinoma development
    Hedwig P van de Nieuwenhof
    Department of Obstetrics and Gynaecology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Histopathology 57:351-62. 2010
    ....
  79. ncbi Rapid groin recurrence of a vulvar carcinoma with invasion of the femoral vessels and the importance of the initial groin dissection in the staging surgery
    E Buxant
    Department of Gynaecology, Erasme Hospital, Free University of Brussels, ULB, Brussels, Belgium
    Acta Chir Belg 105:418-9. 2005
    ..The disease spreads from the vulva through embolization to the locoregional lymphatic station, the inguinofemoral nodes. The single most important prognostic factor is the presence or absence of nodal disease...
  80. ncbi Sparing of saphenous vein during inguinal lymphadenectomy for vulval malignancies
    Xiaoling Zhang
    Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, 250117, Shandong, PR China
    Gynecol Oncol 105:722-6. 2007
    ..This work was set out to investigate the effect of saphenous vein preservation during inguinal lymphadenectomy for patients with vulval malignancies...
  81. ncbi Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma
    Hedwig P van de Nieuwenhof
    Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre, The Netherlands
    Mod Pathol 24:297-305. 2011
    ..Patients with lichen sclerosus with dyskeratosis and parakeratosis, hyperplasia and/or basal cellular atypia should be kept under close surveillance as these lesions also tend to progress to squamous cell carcinoma...
  82. ncbi Primary ectopic breast cancer presenting as a vulvar mass
    Gilberto Lopes
    Department of Oncology, Johns Hopkins Singapore International Medical Center, Singapore
    Clin Breast Cancer 7:278-9. 2006
    ..Its treatment usually entails surgical resection with lymph node dissection. Adjuvant therapy should be guided by the same principles as in orthotopic breast carcinoma...
  83. pmc Cervical and vulvar cancer risk in relation to the joint effects of cigarette smoking and genetic variation in interleukin 2
    Shehnaz K Hussain
    Program in Epidemiology, Division of Public Health Sciences, University of Washington, Seattle, WA, USA
    Cancer Epidemiol Biomarkers Prev 17:1790-9. 2008
    ..87; 95% CI, 1.00-3.48), and for carriership of the TTCC/TTCC diplotype (IOR, 2.08; 95% CI, 1.01-4.30). These results suggest that cervical and vulvar SCC risk among cigarette smokers is modified by genetic variation in IL2...
  84. ncbi A cluster of vulvar cancer and vulvar intraepithelial neoplasia in young Australian indigenous women
    John R Condon
    Services, Systems and Society Division, Menzies School of Health Research, PO Box 41096, Casuarina, NT, 0811, Australia
    Cancer Causes Control 20:67-74. 2009
    ..To describe the epidemiological features of a possible disease cluster of vulvar cancer and pre-cancers in Australian Indigenous women living in the Northern Territory (NT) of Australia...
  85. ncbi Radical versus conservative surgery for vulvar carcinoma
    M Arvas
    Istanbul University, Cerrahpasa School of Medicine, Gynecologic Oncology Division, Istanbul, Turkey
    Int J Gynaecol Obstet 88:127-33. 2005
    ..The comparison of the radical and conservative surgical approaches for vulvar carcinoma in relation to the rate of recurrence and complications...
  86. ncbi Current controversies in the management of patients with early-stage vulvar cancer
    Maaike H M Oonk
    Department of Gynecologic Oncology, University Medical Center Groningen, Groningen, The Netherlands
    Curr Opin Oncol 22:481-6. 2010
    ..The main focus will be on the procedures for assessing the sentinel node and the treatment of those with evidence of metastatic involvement...
  87. ncbi Impact of inguinal dissection on prognosis of early-stage squamous cell carcinoma of the vulva--a retrospective analysis
    J R Kouvaris
    Department of Radiology Radiotherapy, Aretaeion Hospital, University of Athens, Greece
    Onkologie 26:564-7. 2003
    ..Inclusion of inguinal lymphadenectomy in the surgical procedure is a potential prognostic factor for squamous cell vulvar carcinoma...
  88. ncbi The accuracy of the sentinel lymph node concept in early stage squamous cell vulvar carcinoma
    Jakub Radziszewski
    Department of Brachytherapy, The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
    Gynecol Oncol 116:473-7. 2010
    ..The purpose of the study was to determine the feasibility and accuracy of the sentinel lymph node (SLN) identification in vulvar carcinoma patients...
  89. pmc Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins
    I Bourgault Villada
    Institut Cochin, Universite Paris Descartes, CNRS UMR 8104, Departement d Immunologie, Hopital Cochin, Paris, France
    Clin Exp Immunol 159:45-56. 2010
    ..In order to build a therapeutic anti-HPV-16 vaccine, E6/2 (14-34) and E6/4 (45-68) fragments thus appear to be good candidates to increase HPV-specific effector T lymphocyte responses and clear classic VIN (BP) disease lesions...
  90. ncbi Groin recurrence in carcinoma of the vulva: management and outcome
    G Cormio
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Bari, Bari, Italy
    Eur J Cancer Care (Engl) 19:302-7. 2010
    ..Groin recurrences from vulvar carcinoma carry a poor prognosis. Multi-modal treatment may result in a palliation of the disease, and a very limited number of patients have long-term survival...
  91. ncbi The simplex (differentiated) variant of vulvar intraepithelial neoplasia
    Meng Yueh Hsieh
    Department of Dermatology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
    Dermatol Surg 30:948-51. 2004
    ..It is regarded as more likely than "classic" carcinoma in situ to be associated with invasion and can be easily mistaken for benign lesions...
  92. ncbi Outcome and patterns of recurrence for International Federation of Gynecology and Obstetrics (FIGO) stages I and II squamous cell vulvar cancer
    Charuwan Tantipalakorn
    Gynaecological Cancer Centre, Royal Hospital for Women and University of New South Wales, Sydney, Australia
    Obstet Gynecol 113:895-901. 2009
    ....
  93. ncbi Differentiated-type vulval intraepithelial neoplasia has a high-risk association with vulval squamous cell carcinoma
    Lois J Eva
    Pan Birmingham Cancer Centre, Birmingham, UK
    Int J Gynecol Cancer 19:741-4. 2009
    ..To assess the potential malignant risk of vulval premalignant conditions, in particular, to investigate whether there is a difference in the cancer risk between women with the 2 types of vulval intraepithelial neoplasia (VIN)...
  94. ncbi Risk of occult inguinofemoral lymph node metastasis from squamous carcinoma of the vulva
    Jesus Gonzalez Bosquet
    Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 57:419-24. 2003
    ....
  95. ncbi Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study
    Maaike H Oonk
    University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Lancet Oncol 11:646-52. 2010
    ..Our study aimed to assess the association between size of sentinel-node metastasis and risk of metastases in non-sentinel nodes, and risk of disease-specific survival in early stage vulvar cancer...
  96. ncbi Human papillomavirus (HPV) profiles of vulvar lesions: possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination
    Petr Skapa
    Department of Pathology and Molecular Medicine, Charles University, 2nd Medical School, Faculty Hospital Motol, Prague, Czech Republic
    Am J Surg Pathol 31:1834-43. 2007
    ....
  97. ncbi Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy
    Peter Hillemanns
    Department of Obstetrics and Gynecology, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Gynecol Oncol 100:271-5. 2006
    ..To evaluate various treatment modalities for vulvar intraepithelial neoplasia (VIN) in relation to possible risk factors for recurrence...
  98. ncbi Gynaecologic cancer complicating pregnancy: an overview
    Frederic Amant
    Obstetrics and Gynaecology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium
    Best Pract Res Clin Obstet Gynaecol 24:61-79. 2010
    ..Firstly, we describe general diagnostic and cancer-treatment-related problems. In the second part, organ pathology including breast, cervical, ovarian, endometrial and vulvar cancer is discussed...
  99. ncbi Review of squamous premalignant vulvar lesions
    H P van de Nieuwenhof
    Department of Obstetrics and Gynaecology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Crit Rev Oncol Hematol 68:131-56. 2008
    ..In this review we will discuss the history, epidemiology, aetiology, histology, clinical characteristics, treatment options, malignant potential and prevention strategies of the three squamous premalignant vulvar lesions...
  100. pmc Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
    Marij J P Welters
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
    Proc Natl Acad Sci U S A 107:11895-9. 2010
    ..Foxp3(+) T cells have been associated previously with impaired immunity in malignancies. Here we demonstrate that the vaccine-prompted level of this population is associated with early treatment failure...
  101. ncbi Human papillomavirus infections and vulvar disease development
    Suzanne M Garland
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Medical University of Vienna, Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria
    Cancer Epidemiol Biomarkers Prev 18:1777-84. 2009
    ....

Research Grants13

  1. Structure/Function of Human Papillomavirus Oncoproteins
    Ronen Marmorstein; Fiscal Year: 2006
    ....
  2. Vulvar Disease and Bladder and Bowel Symptoms
    Colleen Kennedy; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  3. BREAST CANCER AND GENE POLYMORPHISMS IN CHINESE WOMEN
    Chu Chen; Fiscal Year: 2003
    ..Our ultimate goal is to provide information to identify women at high risk of breast cancer, and to aid in the formulation of prevention strategies for these women. ..
  4. MOLECULAR EPIDEMIOLOGY OF LUNG CANCER
    Chu Chen; Fiscal Year: 2010
    ..g. Rosaceae fruits and Cruciferae vegetables), and food-derived nutrients (e.g. carotenoids, vitamin C, and vitamin E). ..
  5. ORAL CANCER: MOLECULAR PROFILES & CLINICAL OUTCOMES
    Chu Chen; Fiscal Year: 2010
    ..HPV plays an important etiologic role in some oropharyngeal cancers, we plan to determine and incorporate HPV genotypes in the analyses and interpretation of the study findings. ..
  6. A Therapeutic Vaccine for HPV 16-Positive Head and Neck Cancer
    Maura Gillison; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  7. Therapeutic DNA-MVA prime boost vaccination for HPV disease
    Cornelia Trimble; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  8. Molecular Epidemiology of Endometrial Cancer
    Chu Chen; Fiscal Year: 2007
    ..Efforts will also be devoted to generating risk indices through statistical modeling that integrate potential effects of genetic variants in the estrogen metabolism pathway and/or DNA repair pathways. ..
  9. A Molecular Signature of Early Cervical Carcinoma
    Concepcion Diaz Arrastia; Fiscal Year: 2007
    ..I propose to identify a genomic and proteomic signature of cervical cancer that will predict the aggressive behavior of the tumor and function clinically to develop molecular-based treatment plans. ..
  10. Vulvar vestibulitis trial: Desipramine-Lidocaine
    David Foster; Fiscal Year: 2006
    ..equally effective or is one superior to the other? Is there any benefit from combined local and systemic treatments? And finally, do genetic characteristics and tissue cytokine concentrations influence treatment response? ..
  11. THERAPEUTIC VACCINES FOR HPV DISEASES
    Cornelia Trimble; Fiscal Year: 2005
    ..These facilities will be used to develop Dr. Trimble's ability to design and execute clinical trials evaluating preneoplastic HPV-associated lesions of the female lower genital tract. ..
  12. A Phase I/II Trial of a Therapeutic HPV Vaccine
    Cornelia Trimble; Fiscal Year: 2004
    ....
  13. Effect of Male Circumcision on Penile HPV Infection
    JENNIFER SUSAN SMITH; Fiscal Year: 2010
    ..If male circumcision is found to be effective and safe in reducing HPV infection or penile lesions in men, it could in turn reduce HPV prevalence and associated cervical neoplasia in women. ..